NCT00030186View on ClinicalTrials.gov

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions

Leukemia, Myeloid

Interventions

DRUG

CEP-701 60mg

60mg orally 2 times a day for 28 days

DRUG

Cep-701 80mg

80mg 2 times a day, dependent upon response to cycle 1

DRUG

Cep-701 40mg

40mg 2 times a day, dependent upon response to cycle 1

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cephalon

INDUSTRY